Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of votoplam in Huntington's disease
2025-522227-99-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial in Huntington disease (HD) comparing votoplam with placebo (2 arms). Primary endpoint: Change from baseline to Month 36 in cUHDRS score. Planned start Jul 2026; status: authorised.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2025-522227-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522227-99-00.